David Dongliang Ge
Dr. David Dongliang Ge is CEO and President of Apostle. Apostle Inc is a biotechnology company in Sunnyvale, CA focusing on novel bioinformatics-enabled nanotechnologies for cancer early detection. Previously, he was President of BioSciKin Co. and Simcere Diagnostics Co., two global biotechnology companies headquartered in Nanjing, China focusing on the licensing and sales of diagnostic technologies. Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences, where he founded and provided leadership to the bioinformatics group and provided the strategic input to related infrastructure and process. Dr. Ge and his group led the phylogenomic analytical support for the critical regulatory approval of Sovaldi, a world-leading anti-HCV drug. In 2014 and 2015, Dr. Ge was invited to be a member of the U.S. National Human Genome Research Institute Special Emphasis Panel. Prior to Gilead, he was appointed as Assistant Professor of Biostatistics and Bioinformatics and Assistant Professor in Medicine at Duke University School of Medicine. He received his Ph.D. of Biostatistics and Genetic Epidemiology from Peking Union Medical College and Chinese Academy of Medical Sciences in 2004. Dr. Ge’s work in discovering the IL28B genetic variants associated with the clinical treatment responses, published in Nature in 2009, has received over 3000 times of citations to date. The invention was licensed to LabCorp and Quest Diagnostics, and has become clinical diagnostic services since then (LabCorp 480630 and Quest AccuType® IL28). The U.S. FDA has cited this ground-breaking discovery in several of the agency’s guidance for industry. Dr. Ge has authored or co-authored over 70 peer-reviewed articles, among which are 5 articles in Nature and 1 in Science, in total receiving over 15,000 citations. Dr. Ge was named by the U.S. Genome Technology magazine as one of the “Rising Stars” in 2009, and by the U.K. Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015.